Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Introduction: Pancreatic cancer is the fourth-leading cause of cancer-related death in developed countries. Despite advances in systemic chemotherapy, the mainstay of curative therapy for non-metastatic disease is surgical resection. However, the perioperative period is characterised by stress and inflammatory reactions that can contribute to metastatic spread and disease recurrence. Catecholamines and prostaglandins play a crucial role in these reactions. Therefore, a drug repurposing of betablockers and cyclooxygenase inhibitors seems reasonable to attenuate tumour-associated inflammation by inhibiting psychological, surgical and inflammatory stress responses. This may cause a relevant antitumourigenic and antimetastatic effect during the perioperative period, a window for cancer-directed therapy that is currently largely unexploited. Methods and analysis: This is a prospective, single-centre, two-arm randomised, patient and observer blinded, placebo-controlled, phase-II trial evaluating safety and feasibility of combined perioperative treatment with propranolol and etodolac in adult patients with non-metastatic cancer of the pancreatic head undergoing elective pancreatoduodenectomy. 100 patients fulfilling the eligibility criteria will be randomised to perioperative treatment for 25 days perioperatively with a combination of propranolol and etodolac or placebo. Primary outcome of interest will be safety in terms of serious adverse events and reactions within 3 months. Furthermore, adherence to trial medication will be assessed as feasibility outcomes. Preliminary efficacy data will be evaluated for the purpose of power calculation for a potential subsequent phase-III trial. The clinical trial is accompanied by a translational study investigating the mechanisms of action of the combined therapy on a molecular basis. Ethics and dissemination: The PROSPER-trial has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4042875) and the Ethics Committee of the Medical Faculty of the University of Heidelberg (reference number AFmo-385/2018). The final trial results will be published in a peer-reviewed journal and will be presented at appropriate national and international conferences. Trial registration numbers: DRKS00014054; EudraCT number: 2018-000415-25.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The trial protocol was published as open-access publication [9] and the trial was registered before inclusion of the first patient in the German Clinical Trials Register (DRKS00014054).”
From Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Bassi, C., Marchegiani, G., Dervenis, C., Sarr, M., Abu Hilal, M., Adham, M., Allen, P., Andersson, R., Asbun, H. J., Besselink, M. G., et al. (2017) · Surgery · doi:10.1016/j.surg.2016.11.014 · Cited by 4,276
Self-citationWente, M. N., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., Traverso, L. W., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.05.005 · Cited by 3,053
Self-citationFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Wente, M. N., Veit, J. A., Bassi, C., Dervenis, C., Fingerhut, A., Gouma, D. J., Izbicki, J. R., Neoptolemos, J. P., Padbury, R. T., Sarr, M. G., et al. (2007) · Surgery · doi:10.1016/j.surg.2007.02.001 · Cited by 2,616
Self-citationKamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Cited by
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“The study includes an ancillary translational section to assess the mechanism of action of the combination [91].”
BackgroundDrug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials
Ioakeim‐Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza‐Pascual‐Salcedo, M., Miguel, A. G., Orlando, V., González‐Rubio, F., Fanlo, A., AZA, C. L., Ostasz, E., et al. (2023) · Cancers · doi:10.3390/cancers15112972 · Cited by 35
O’Logbon, J., Tarantola, L., Williams, N. R., Mehta, S., Ahmed, A., & Davies, E. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06262-2 · Cited by 30
Spilsbury, K., Tuesley, K., Pearson, S., Coory, M. D., Donovan, P. J., Steer, C., Stewart, L. M., Pandeya, N., & Jordan, S. J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00097 · Cited by 18
Hüttner, F. J., Klotz, R., Giese, N. A., Kong, B., Ahmed, A., Merz, D., Pöchmann, A., Burghaus, I., Hackert, T., Strobel, O., et al. (2025) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-025-03735-3 · Cited by 15
“Peripheral blood samples were collected at several points of time as outlined in the published protocol [9].”
InfluentialSelf-citation
Metadata
- Authors
- Hüttner, F. J., Rooman, I., Bouche, G., Knebel, P., Hüsing, J., Mihaljevic, A. L., Hackert, T., Strobel, O., Büchler, M. W., & Diener, M. K.
- Affiliations
- Heidelberg University (DE)
- Vrije Universiteit Brussel (BE)
- Anticancer Fund (BE)
- Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
- Corresponding author
- Büchler, Markus W
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2020-09
- Volume
- 10
- Issue
- 9
- Pages
- e040406
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC7528424
- OpenAlex
- W3089876597
- Semantic Scholar
- 21ea4db58abc15f2bf4d0ae12867c19fa3098d33
- Cited by
- 13
- References
- 30
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Het Anti-Kankerfonds (Anticancer Fund), Brussels, Belgium (A56)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- pancreatic cancer, drug repurposing, propranolol, etodolac, perioperative therapy, pancreaticoduodenectomy, beta-blockers, cyclooxygenase inhibitors, tumour-associated inflammation, catecholamines, prostaglandins, feasibility and safety, medication adherence
- MeSH terms
- Adult, Humans, Pancreatectomy, Propranolol, Prospective Studies, Randomized Controlled Trials as Topic, Etodolac, Clinical Trials, Phase II as Topic, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial. https://app.cochat.ai/papers/10.1136/bmjopen-2020-040406
- The paper
- Hüttner, F. J., Rooman, I., Bouche, G., Knebel, P., Hüsing, J., Mihaljevic, A. L., Hackert, T., Strobel, O., Büchler, M. W., & Diener, M. K. (2020). Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial. BMJ Open. https://doi.org/10.1136/bmjopen-2020-040406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
